Skip to main content
QMSQMS
QMS
  • Welcome to your QMS
  • Quality Manual
  • Procedures
    • GP-001 Control of documents
    • GP-002 Quality planning
    • GP-003 Audits
    • GP-004 Vigilance system
    • GP-005 Human Resources and Training
    • GP-006 Non-conformity, Corrective and Preventive actions
    • GP-007 Post-market surveillance
    • GP-008 Product requirements
    • GP-009 Sales
    • GP-010 Purchases and suppliers evaluation
    • GP-011 Provision of service
    • GP-012 Design, redesign and development
      • Templates
        • T-012-019 SOUP
        • T-012-021 Product Design Phase 1 Checklist
        • T-012-022 Software Design Phase 2 Checklist
        • T-012-023 Software Development Plan
        • T-012-024 Software Candidate Release Phase 3 Checklist
        • T-012-025 Software Verification Phase 4 Checklist
        • T-012-026 Product Validation Phase 5 Checklist
        • T-012-028 Software Requirement Specification
        • T-012-029 Software Architecture Description
        • T-012-030 Software Configuration Management Plan
        • T-012-031 Product Requirements Specification
        • T-012-033 Software Tests Plan
        • T-012-034 Software Test Description
        • T-012-035 Software Test Run
        • T-012-037 Labeling and IFU Requirements
        • T-012-038 Verified Version Release
        • T-012-039 Validated Version Transfer
        • T-012-040 Documentation level FDA
        • T-012-041 Software Classification 62304
        • T-012-043 Traceability Matrix
        • T-012-044 SOUP Request and Approval Form
        • obsolete
    • GP-013 Risk management
    • GP-014 Feedback and complaints
    • GP-015 Clinical evaluation
    • GP-016 Traceability and identification
    • GP-017 Technical assistance service
    • GP-018 Infrastructure and facilities
    • GP-019 Software validation plan
    • GP-020 QMS Data analysis
    • GP-021 Communications
    • GP-022 Document translation
    • GP-023 Change control management
    • GP-024 Predetermined Change Control Plan
    • GP-025 Usability and Human Factors Engineering
    • GP-027 Corporate Governance
    • GP-028 AI Development
    • GP-029 Software Delivery and Commissioning
    • GP-030 Cyber Security Management
    • GP-050 Data Protection
    • GP-051 Security violations
    • GP-052 Data Privacy Impact Assessment (DPIA)
    • GP-100 Business Continuity (BCP) and Disaster Recovery plans (DRP)
    • GP-101 Information security
    • GP-200 Remote Data Acquisition in Clinical Investigations
    • GP-026 Market-specific product requirements
    • GP-110 Esquema Nacional de Seguridad
  • Records
  • Legit.Health Plus Version 1.1.0.0
  • Legit.Health Plus Version 1.1.0.1
  • Legit.Health Utilities
  • Licenses and accreditations
  • Applicable Standards and Regulations
  • Pricing
  • Public tenders
  • Procedures
  • GP-012 Design, redesign and development
  • Templates
  • T-012-038 Verified Version Release

T-012-038 Verified Version Release

Actors​

NameTitleMeaningApproved Date & Time

Change history​

RevisionSummaryDate

Project information​

  • Project title:
  • Version number:
  • Release branch: release/W.X.Y.Z

Pre-requisites verification​

Before completing this document, verify that all required Phase 4 activities have been completed:

Pre-requisiteReference DocumentCompleted
T-012-024 Software Candidate Release Phase 3 Checklist approvedT-012-024
Release Candidate built from release branch
T-012-033 Software Test Plan availableT-012-033
T-012-034 Software Test Description availableT-012-034
T-012-035 Software Test Report completedT-012-035
All test cases executed per test plan
Residual anomalies identified and risk-assessed

Release Metadata​

FieldValue
Version number
Version tag
Release branch
Build date
Release Candidate identifier

Verifications​

Instructions

Summarize the conclusions of the review process based on the Quality Management System. Verify that:

  • All test cases have been executed and results documented
  • Quality controls were completed and satisfactory
  • The software is safe to use based on residual anomaly risk assessment
  • The software complies with IEC 62304 requirements
  • The software meets its intended use and quality standards

Write each point as a clear, affirmative verification.

Verification itemStatusComments
All unit tests passed
All integration tests passed
All system tests passed
All residual anomalies have acceptable risk assessments
Software verification is complete per IEC 62304 clause 5.5-5.7
Software is ready for validation activities in Phase 5

Technical Specifications​

Instructions

Describe the scope of the release in terms of functional requirements:

  • Number of software requirements verified in this version
  • Reference to R-TF-012-028 Software Requirement Specification
  • Reference to R-TF-012-043 Traceability Matrix for requirement coverage
  • Summary of key features/capabilities in this version
SpecificationValue/Reference
Total software requirements
Requirements verified
Software Requirement SpecificationR-TF-012-028
Traceability MatrixR-TF-012-043

Test Execution Summary​

Test categoryTotal testsPassedFailedBlockedPass rate
Unit tests
Integration tests
System tests
Regression tests
Total

Known Residual Anomalies​

Instructions

List all known residual anomalies detected during verification. For each anomaly:

  • Provide a unique identifier (e.g., bug tracker ID)
  • Describe the anomaly briefly
  • Document the risk assessment (severity, probability, risk level)
  • Justify why the anomaly is acceptable for release
  • Describe any mitigation measures

If no residual anomalies exist, state "No residual anomalies identified."

IDSummarySeverityProbabilityRisk LevelJustification/MitigationAcceptable

Version Release Authorization​

Instructions

The JD-007 (Technical Manager) formally releases this verified version for Phase 5 validation activities.

Release statement​

This version has been verified according to GP-012 Software Design and Development procedure and IEC 62304 requirements. All verification activities are complete and documented. Known residual anomalies have been assessed and are acceptable. This version is authorized to proceed to Phase 5 Product Validation.

Approval​

RoleNameSignatureDate
JD-007 (Technical Manager)
JD-003 (Quality Manager)

References​

  • T-012-025 Software Verification Phase 4 Checklist
  • T-012-033 Software Test Plan
  • T-012-034 Software Test Description
  • T-012-035 Software Test Report
  • R-TF-012-028 Software Requirement Specification
  • R-TF-012-043 Traceability Matrix
  • R-TF-013-002 Risk Management Record (for residual anomaly risk assessment)
Previous
T-012-037 Labeling and IFU Requirements
Next
T-012-039 Validated Version Transfer
  • Actors
  • Change history
  • Project information
  • Pre-requisites verification
  • Release Metadata
  • Verifications
  • Technical Specifications
  • Test Execution Summary
  • Known Residual Anomalies
  • Version Release Authorization
    • Release statement
    • Approval
  • References
All the information contained in this QMS is confidential. The recipient agrees not to transmit or reproduce the information, neither by himself nor by third parties, through whichever means, without obtaining the prior written permission of Legit.Health (AI Labs Group S.L.)